Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus R-CHOP in double expression DLBCL
NCT05933967Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Shandong Cancer Hospital. Started Jun 2023; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05933967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933967.